{"public_id":"cl_df5b0f9c200a1ad5d4b8fb484c271e5f","status":"active","superseded_by_public_id":null,"corpus_id":9449984,"text":"Outcomes in prostate cancer trials should be reported independently for PSA, imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response.","confidence":0.93,"paper":{"corpus_id":9449984,"title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.","url":"https://sah.borca.ai/papers/9449984"},"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0da72348243acbcee406e0607564248c","name":"bone scan","description":"An imaging modality used to detect bone metastases, reported as 'new lesions' or 'no new lesions' in prostate cancer trials.","types":["imaging method","outcome measure"],"url":"https://sah.borca.ai/concepts/co_0da72348243acbcee406e0607564248c"},{"public_id":"co_4948f18c289c2266133a04ad7e2a3d6d","name":"prostate-specific antigen","description":"A biomarker used as one independently reported outcome measure in prostate cancer clinical trials.","types":["biomarker","outcome measure"],"url":"https://sah.borca.ai/concepts/co_4948f18c289c2266133a04ad7e2a3d6d"},{"public_id":"co_5d52c2c274b4bb6a4971b1f4d0ee1b55","name":"soft-tissue disease","description":"Non-bone tumor manifestations assessed by RECIST as an independently reported imaging outcome in prostate cancer trials.","types":["disease manifestation"],"url":"https://sah.borca.ai/concepts/co_5d52c2c274b4bb6a4971b1f4d0ee1b55"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_df5b0f9c200a1ad5d4b8fb484c271e5f"}